Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.
August 22, 2022 08:00 ET
|
Belite Bio, Inc
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in...
Belite Bio Reports First Half 2022 Operational Highlights and Financial Results
August 10, 2022 21:51 ET
|
Belite Bio, Inc
-LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD -A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial...
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
August 01, 2022 16:10 ET
|
Belite Bio, Inc
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host...
Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease
July 19, 2022 16:05 ET
|
Belite Bio, Inc
LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1)There are currently no approved treatments for STGD1Approximately 30,000 patients...
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
May 12, 2022 16:30 ET
|
Belite Bio, Inc
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable...
Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
May 05, 2022 08:00 ET
|
Belite Bio, Inc
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjectsA trend for stabilized or improved visual acuity was observedObserved adverse events were...
Belite Bio Announces Closing of $36 Million Initial Public Offering
May 03, 2022 16:30 ET
|
Belite Bio, Inc
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable...
Belite Bio Receives FDA Fast Track Designation For LBS-008
May 03, 2022 06:50 ET
|
Belite Bio, Inc
LBS-008 (aka Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1)There are currently no approved treatments for STGD1A 2-year Phase 2 trial in...
Belite Bio Announces Pricing of $36 Million Initial Public Offering
April 28, 2022 18:59 ET
|
Belite Bio, Inc
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable...